Global Epilepsy Market 2017-2028 | DelveInsight

As per the National Institute of Neurological Disorders and Stroke (NINDS), Epilepsy is a
spectrum of brain disorders ranging from severe, life-threatening and disabling, to ones that
are much more benign.

Epilepsy disrupts the normal pattern of neuronal activity, causing strange sensations,
emotions, and behaviour. Short attention blackouts, dazed behaviour, memory gaps,
mumbling or no response, sudden falls, frequent stumbling or unusual clumsiness, head
nodding or rapid blinking, sudden stomach pain followed by confusion and sleepiness, are the
most commonly found symptoms that are shown by the patients during the onset of the
disease.

DelveInsight’s ‘Epilepsy Market - Market Insights, Epidemiology and Market Forecast-

2028’ Report delivers a comprehensive Epilepsy market overview, its types, symptoms,
origin, causes, and symptoms.

Request for sample pages

Epilepsy Market Report

The Epilepsy Market report covers an in-depth layout of Epilepsy epidemiological trends
including Epilepsy Diagnosis rates, Epilepsy prevalence and incidence. Furthermore, the
report provides the 10-year forecast of the Epilepsy Epidemiology.

The total Epilepsy market size calculated in the 7MM was USD 2,984 Million in 2017.
DelveInsight’s analysts estimate that the market is expected to show positive growth in the
forecast period.
Moreover, DelveInsight estimates that the US market is expected to grow at a CAGR rate of
8.85% for a study period of 2017-2028.

Epilepsy Epidemiology analysis

The available literature revealed that the most epilepsy syndromes are equally or more
commonly found in males than in females suggesting a higher male preponderance.

The United States approximately has a total of 3.4 million Epilepsy prevalent population, as
estimated by the Epilepsy Foundation, with over 150,000 new Epilepsy diagnosed cases each
year.

As per DelveInsight estimates, in EU5, the UK accounted for the highest the highest
diagnosed prevalent population of Epilepsy with 443,603 cases, followed by Germany with a
total of diagnosed Epileptic prevalent population of 386,725 in 2017.

Whereas Japan had 899,420 diagnosed Epileptic patients in 2017.

DelveInsight’s Epilepsy Market Report comprises a well-researched data on Epilepsy

epidemiology trends in the 7MM, providing incidence, prevalence, diagnosis, and Epilepsy
forecast analysis stating the plausible reasons for the prevailing Epilepsy market trends.

Epilepsy Therapeutics landscape

The Epilepsy treatment market is highly dependent on a combination of medications, diet

therapy, and surgery. It is important to understand that the Epilepsy treatment regimen
depends highly on the condition of the patient.

The most prescribed and one of the earlier Epilepsy treatment options is Anti-Epileptic
Medications (AEDs).
Cenobamate (YKP3089) by SK Pharmaceuticals, Fintepla (ZX008) by Zogenix,
Ganaxolone by Marinus Pharmaceuticals and many others, the Epilepsy therapy market size
is expected to leap forward.

The Epilepsy treatment market is likely to experience significant annual growth over the
2017–2028 study period, as major-market sales are expected to increase by 2028.

Owing to the positive outcomes of the several drug candidates during the developmental
stage, the Epilepsy therapy market is expected to strive forward.

Upcoming Epilepsy therapies

A detailed layout of the Mechanism of Actions, pharmacological actions, administration

routes, and side effects (if, any) is provided in the DelveInsight’s Epilepsy Market Insights
report.

The launch of emerging Epilepsy therapies such Cenobamate (YKP3089), Fintepla

(ZX008) and Ganaxolone are anticipated to garner maximum Epilepsy market share.

As per DelveInsight’s analysts, upcoming Epilepsy drugs will positively impact the Epilepsy
treatment market.

Companies involved in advancing Epilepsy Pipeline

Key pharma players in the Epilepsy market are Marinus Pharmaceuticals, Sage Therapeutics,
SK Biopharmaceuticals, UCB, Neurelis, Zogenix, Aquestive Therapeutics, INSYS
Therapeutics, Engage Therapeutics, Zynerba Pharma, and many others. These drug makers
have the full potential to shift the Epilepsy therapy market in a right direction increasing the
value to the Epilepsy market.

Epilepsy Unmet needs

Despite the presence of several therapies for an effective Epilepsy treatment, there still exists
various kinds of unmet needs and treatment challenges that still remain to be overcome.

The need for the better and standard Epilepsy diagnosis, identification of the symptoms, and
significantly effective AEDs that have the potential to cope with the Epilepsy and associated
morbidities still remain.

To address the prevailing unmet needs, a lot of companies mentioned above and many others
including Biogen and CuroNZ are developing therapies to provide better Epilepsy treatments
and investing in R&D in the field.

In conclusion, the increasing prevalence, awareness of the disease, and promising emerging
pipeline therapies will fuel the Epilepsy market size in coming years.